Quest Diagnostics (NYSE:DGX) Sets New 12-Month High – Time to Buy?

by · The Cerbat Gem

Shares of Quest Diagnostics Incorporated (NYSE:DGX – Get Free Report) reached a new 52-week high on Monday . The company traded as high as $165.32 and last traded at $165.09, with a volume of 54117 shares. The stock had previously closed at $163.59.

Analyst Ratings Changes

Several equities analysts recently issued reports on DGX shares. Piper Sandler raised their price target on Quest Diagnostics from $150.00 to $165.00 and gave the company a “neutral” rating in a report on Monday, October 28th. Robert W. Baird raised shares of Quest Diagnostics from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $157.00 to $182.00 in a research note on Wednesday, October 23rd. UBS Group increased their price objective on shares of Quest Diagnostics from $165.00 to $166.00 and gave the company a “neutral” rating in a report on Wednesday, October 23rd. Truist Financial lifted their target price on shares of Quest Diagnostics from $158.00 to $165.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Finally, Baird R W raised shares of Quest Diagnostics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 23rd. Nine investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $164.58.

Get Our Latest Stock Report on DGX

Quest Diagnostics Stock Down 0.7 %

The company has a current ratio of 1.25, a quick ratio of 1.17 and a debt-to-equity ratio of 0.83. The firm’s 50 day moving average price is $154.84 and its two-hundred day moving average price is $148.46. The company has a market capitalization of $18.13 billion, a price-to-earnings ratio of 21.99, a price-to-earnings-growth ratio of 2.83 and a beta of 0.89.

Quest Diagnostics (NYSE:DGX – Get Free Report) last announced its quarterly earnings results on Tuesday, October 22nd. The medical research company reported $2.30 earnings per share for the quarter, topping analysts’ consensus estimates of $2.26 by $0.04. Quest Diagnostics had a return on equity of 15.25% and a net margin of 8.82%. The firm had revenue of $2.49 billion for the quarter, compared to the consensus estimate of $2.43 billion. During the same quarter in the previous year, the business earned $2.22 earnings per share. The business’s revenue was up 8.5% compared to the same quarter last year. Sell-side analysts anticipate that Quest Diagnostics Incorporated will post 8.9 earnings per share for the current fiscal year.

Quest Diagnostics Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 29th. Stockholders of record on Tuesday, January 14th will be paid a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.85%. The ex-dividend date of this dividend is Tuesday, January 14th. Quest Diagnostics’s dividend payout ratio is presently 40.32%.

Insider Buying and Selling

In related news, CAO Michael J. Deppe sold 18,755 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $154.05, for a total value of $2,889,207.75. Following the completion of the sale, the chief accounting officer now directly owns 34,941 shares in the company, valued at approximately $5,382,661.05. The trade was a 34.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Karthik Kuppusamy sold 1,990 shares of Quest Diagnostics stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $153.26, for a total value of $304,987.40. Following the completion of the transaction, the senior vice president now directly owns 11,459 shares of the company’s stock, valued at $1,756,206.34. This represents a 14.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 22,520 shares of company stock valued at $3,472,728. Company insiders own 0.79% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. State Street Corp lifted its position in shares of Quest Diagnostics by 1.4% during the 3rd quarter. State Street Corp now owns 5,263,231 shares of the medical research company’s stock worth $817,117,000 after buying an additional 70,578 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Quest Diagnostics by 1.5% in the third quarter. Geode Capital Management LLC now owns 2,616,653 shares of the medical research company’s stock worth $404,838,000 after acquiring an additional 39,217 shares during the last quarter. Davis Selected Advisers boosted its stake in shares of Quest Diagnostics by 0.4% in the 2nd quarter. Davis Selected Advisers now owns 2,390,828 shares of the medical research company’s stock valued at $327,257,000 after purchasing an additional 9,665 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Quest Diagnostics by 6.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,109,515 shares of the medical research company’s stock valued at $288,758,000 after purchasing an additional 129,395 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale increased its position in Quest Diagnostics by 2.1% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 748,680 shares of the medical research company’s stock worth $115,621,000 after purchasing an additional 15,047 shares in the last quarter. Institutional investors own 88.06% of the company’s stock.

Quest Diagnostics Company Profile

(Get Free Report)

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Further Reading